[go: up one dir, main page]

WO2018005328A8 - Bictegravir deutérié - Google Patents

Bictegravir deutérié Download PDF

Info

Publication number
WO2018005328A8
WO2018005328A8 PCT/US2017/039207 US2017039207W WO2018005328A8 WO 2018005328 A8 WO2018005328 A8 WO 2018005328A8 US 2017039207 W US2017039207 W US 2017039207W WO 2018005328 A8 WO2018005328 A8 WO 2018005328A8
Authority
WO
WIPO (PCT)
Prior art keywords
bictegravir
deuterated
deuterium
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/039207
Other languages
English (en)
Other versions
WO2018005328A1 (fr
Inventor
Roger D. Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of WO2018005328A1 publication Critical patent/WO2018005328A1/fr
Publication of WO2018005328A8 publication Critical patent/WO2018005328A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des formes deutériées de bictegravir, et ses sels pharmaceutiquement acceptables. Dans un aspect, l'invention prévoit un composé de Formule I : ou son sel pharmaceutiquement acceptable, chacun de Y1, Y2, Y3, Y4a, Y4b, Y5a, Y5b, Y6, Y7a, Y7b, Y8, Y9, Y10a, Y10b, Y11a, et Y11b étant indépendamment de l'hydrogène ou du deutérium; à condition que si chacun de Y1, Y2, Y3, Y4a, Y4b, Y5a, Y5b, Y6, Y7a, Y7b, Y8, Y9, Y10a, Y10b, et Y11a est l'hydrogène, alors Y11b est du deutérium.
PCT/US2017/039207 2016-06-27 2017-06-26 Bictegravir deutérié Ceased WO2018005328A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662355105P 2016-06-27 2016-06-27
US62/355,105 2016-06-27

Publications (2)

Publication Number Publication Date
WO2018005328A1 WO2018005328A1 (fr) 2018-01-04
WO2018005328A8 true WO2018005328A8 (fr) 2018-02-15

Family

ID=60787625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/039207 Ceased WO2018005328A1 (fr) 2016-06-27 2017-06-26 Bictegravir deutérié

Country Status (1)

Country Link
WO (1) WO2018005328A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862325B (zh) * 2018-08-28 2020-08-25 重庆博腾制药科技股份有限公司 一种(1r,3s)-3-氨基-1-环戊醇及其盐的制备方法
EP3653629A1 (fr) * 2018-11-16 2020-05-20 Sandoz AG Sels d'addition d'acide d'un inhibiteur de transfert de brins de l'intégrase
CN110229174A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 Bictegravir原料药基因毒性杂质的合成方法
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151361A1 (fr) * 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Dérivés de carbamoylpyridone
PH12019501848A1 (en) * 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2015039348A1 (fr) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih

Also Published As

Publication number Publication date
WO2018005328A1 (fr) 2018-01-04

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
WO2017075629A3 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
MX2015002040A (es) Baricitinib deuterado.
MX2015001246A (es) Ibrutinib deuterado.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
TN2018000262A1 (en) Substituted piperidine compound and use there of.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
WO2016011390A8 (fr) Agents d'inhibition de l'irak 4
PH12019500480A1 (en) Pyridine compound
HK1249893A1 (zh) 氘代vx-661
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
WO2016014927A3 (fr) Forme cristalline du riboside de nicotinamide
WO2015168286A8 (fr) 4-phénylepipéridines substituées, leur préparation et utilisation
MX2016002794A (es) Compuestos antiproliferativos.
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
WO2015000431A9 (fr) Carbamate de tizoxanide et son utilisation pharmaceutique
MX2015008829A (es) Momelotinib deuterado.
PH12015502118A1 (en) Pyridin-4-yl derivatives
WO2018005328A8 (fr) Bictegravir deutérié
WO2014153495A9 (fr) Nouveaux inhibiteurs de stats3
EP4335500A3 (fr) Procédés de synthèse de dextrométhorphane deutéré
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MY193239A (en) Novel b-lactamase inhibitors
WO2015002755A3 (fr) Composés pour le traitement du paludisme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17820996

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17820996

Country of ref document: EP

Kind code of ref document: A1